Expanded Premaitha Health trading well, investors told
Yourgene Health
0.52p
17:15 07/09/23
Investors in non-invasive prenatal testing-focussed molecular diagnostics group Premaitha Health were told of positive commercial progress in the first half of the current financial year on Tuesday, as they gathered for the company’s annual general meeting.
FTSE AIM All-Share
755.83
16:25 23/04/24
Pharmaceuticals & Biotechnology
21,866.08
16:39 23/04/24
The AIM-traded company was reportedly growing revenues, increasing test volumes and developing expanded capabilities across a broader geographic area following the acquisition of Yourgene Bioscience in March, shareholders were told.
“Our recent Middle East update further demonstrated our ability to secure business in territories where technical excellence and customer focus are paramount to gaining competitive advantage, and we have a strong pipeline of similar opportunities,” said chairman Adam Reynolds.
“The UK litigation continues to be a distraction, with an initial ruling anticipated before the end of the year. In the meantime, we will continue to pursue our strategy of geographic and product diversification, coupled with a sharp focus on achieving profitability within the current financial year.
“We believe this strategy will ensure that, whatever the outcome of the UK disputes, Premaitha is a business that will succeed in the rapidly expanding global market for NIPT and clinical genetic testing.”